Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Yabing Guo, Vladimir Marquez et al.|The Lancet|2023Cited by 514
Sensitivity and Specificity of Des-Gamma-Carboxy Prothrombin for Diagnosis of Patients with Hepatocellular Carcinomas Varies According to Tumor SizeShinichiro Nakamura, Yasushi Shiratori, Kazuhiro Nouso et al.|The American Journal of Gastroenterology|2006Cited by 165
Potential Role of Hepatocyte Growth Factor, a Novel Angiogenic Growth Factor, in Peripheral Arterial Disease : Downregulation of HGF in Response to Hypoxia in Vascular CellsS. Hayashi, Takeshi Ogihara, R. Morishita et al.|Circulation|1999Cited by 130
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinomaKoji Miyahara, Kazuhide Yamamoto, Kazuhiro Nouso et al.|Journal of Gastroenterology and Hepatology|2011Cited by 90
Long‐term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudineHaruhiko Kobashi, Kazuhide Yamamoto, Yasuhiro Miyake et al.|Hepatology Research|2011Cited by 43